Psychedelic integration has a thinner outcome literature than the assisted-therapy trials that made headlines, particularly for talk therapy after an experience that happened elsewhere. Most of the strong depression data comes from studies that included the psychedelic itself plus psychotherapy. Those trials are context for why integration exists. They are not evidence that Shift Collab administers psychedelics, and we do not. Practice papers describe how clinicians can support people before and after an experience they had in another setting. What happens in the room still depends on you and the person you are working with.
Pilecki, B., Luoma, J. B., & Bathje, G. J. (2021), Harm Reduction Journal. A paper on ethical and legal issues in psychedelic harm-reduction and integration therapy, arguing that clinicians can meet clients before and after personal psychedelic experiences to reduce harm and support benefit, without administering the substances.
Gren, J., Tyls, F., & Lasocik, M. (2023), Frontiers in Psychology. Practice guidelines for mental health specialists on psychedelic integration, covering how to define the work, pace it, and draw on existing psychotherapies. This describes clinical practice. It is not an outcome trial.
Gukasyan, N., Davis, A. K., & Barrett, F. S. (2022), Journal of Psychopharmacology. A 12-month follow-up of psilocybin-assisted treatment for major depression, with two doses plus supportive psychotherapy, found large, durable reductions in depression scores in a small sample. This is assisted therapy with the drug, not standalone integration, and it is not what Shift Collab provides.